Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.

Research output: Contribution to journalArticlepeer-review

Standard

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. / Lip, Gregory; Banerjee, Amitava; Boriani, Giuseppe; Chiang, C-E; Fargo, R; Freedman, S Ben; Lane, Deirdre; Ruff, Christian; Turakhia, Mintu; Werring, David; Patel, Sheena; Moores, Lisa.

In: Chest, 22.08.2018.

Research output: Contribution to journalArticlepeer-review

Harvard

Lip, G, Banerjee, A, Boriani, G, Chiang, C-E, Fargo, R, Freedman, SB, Lane, D, Ruff, C, Turakhia, M, Werring, D, Patel, S & Moores, L 2018, 'Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.', Chest. https://doi.org/10.1016/j.chest.2018.07.040

APA

Lip, G., Banerjee, A., Boriani, G., Chiang, C-E., Fargo, R., Freedman, S. B., Lane, D., Ruff, C., Turakhia, M., Werring, D., Patel, S., & Moores, L. (2018). Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. https://doi.org/10.1016/j.chest.2018.07.040

Vancouver

Author

Lip, Gregory ; Banerjee, Amitava ; Boriani, Giuseppe ; Chiang, C-E ; Fargo, R ; Freedman, S Ben ; Lane, Deirdre ; Ruff, Christian ; Turakhia, Mintu ; Werring, David ; Patel, Sheena ; Moores, Lisa. / Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. In: Chest. 2018.

Bibtex

@article{85d13ec2eab447c5a07664f7367809b0,
title = "Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.",
abstract = "Background The risk of stroke is heterogeneous across different groups of patients with atrial fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios. Methods Systematic literature reviews were conducted to identify relevant articles published from the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). The overall quality of the evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Graded recommendations and ungraded consensus-based statements were drafted, voted on, and revised until consensus was reached. Results For patients with AF without valvular heart disease, including those with paroxysmal AF, who are at low risk of stroke (e.g., CHA2DS2VASc score of 0 in males or 1 in females), we suggest no antithrombotic therapy. The next step is to consider stroke prevention (ie oral anticoagulation therapy) for patients with 1 or more non-sex CHA2DS2VASc stroke risk factors. For patients with a single non-sex CHA2DS2VASc stroke risk factor, we suggest oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel; and for those at high risk of stroke (eg, CHA2DS2VASc ≥2 in males or ≥3 in females), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we recommend or suggest in favor of oral anticoagulation, we suggest using a NOAC rather than adjusted-dose vitamin K antagonist therapy. With the latter, it is important to aim for good quality anticoagulation control with a TTR >70%. Attention to modifiable bleeding risk factors (eg. uncontrolled blood pressure, labile INRs, concomitant use of aspirin or NSAIDs in an anticoagulated patient, alcohol excess) should be made at each patient contact, and HAS-BLED score used to assess the risk of bleeding where high risk patients (≥3) should be reviewed and followed up more frequently. Conclusions Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non-gender CHA2DS2VASc stroke risk factor(s).",
author = "Gregory Lip and Amitava Banerjee and Giuseppe Boriani and C-E Chiang and R Fargo and Freedman, {S Ben} and Deirdre Lane and Christian Ruff and Mintu Turakhia and David Werring and Sheena Patel and Lisa Moores",
year = "2018",
month = aug,
day = "22",
doi = "10.1016/j.chest.2018.07.040",
language = "English",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",

}

RIS

TY - JOUR

T1 - Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.

AU - Lip, Gregory

AU - Banerjee, Amitava

AU - Boriani, Giuseppe

AU - Chiang, C-E

AU - Fargo, R

AU - Freedman, S Ben

AU - Lane, Deirdre

AU - Ruff, Christian

AU - Turakhia, Mintu

AU - Werring, David

AU - Patel, Sheena

AU - Moores, Lisa

PY - 2018/8/22

Y1 - 2018/8/22

N2 - Background The risk of stroke is heterogeneous across different groups of patients with atrial fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios. Methods Systematic literature reviews were conducted to identify relevant articles published from the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). The overall quality of the evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Graded recommendations and ungraded consensus-based statements were drafted, voted on, and revised until consensus was reached. Results For patients with AF without valvular heart disease, including those with paroxysmal AF, who are at low risk of stroke (e.g., CHA2DS2VASc score of 0 in males or 1 in females), we suggest no antithrombotic therapy. The next step is to consider stroke prevention (ie oral anticoagulation therapy) for patients with 1 or more non-sex CHA2DS2VASc stroke risk factors. For patients with a single non-sex CHA2DS2VASc stroke risk factor, we suggest oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel; and for those at high risk of stroke (eg, CHA2DS2VASc ≥2 in males or ≥3 in females), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we recommend or suggest in favor of oral anticoagulation, we suggest using a NOAC rather than adjusted-dose vitamin K antagonist therapy. With the latter, it is important to aim for good quality anticoagulation control with a TTR >70%. Attention to modifiable bleeding risk factors (eg. uncontrolled blood pressure, labile INRs, concomitant use of aspirin or NSAIDs in an anticoagulated patient, alcohol excess) should be made at each patient contact, and HAS-BLED score used to assess the risk of bleeding where high risk patients (≥3) should be reviewed and followed up more frequently. Conclusions Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non-gender CHA2DS2VASc stroke risk factor(s).

AB - Background The risk of stroke is heterogeneous across different groups of patients with atrial fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios. Methods Systematic literature reviews were conducted to identify relevant articles published from the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). The overall quality of the evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Graded recommendations and ungraded consensus-based statements were drafted, voted on, and revised until consensus was reached. Results For patients with AF without valvular heart disease, including those with paroxysmal AF, who are at low risk of stroke (e.g., CHA2DS2VASc score of 0 in males or 1 in females), we suggest no antithrombotic therapy. The next step is to consider stroke prevention (ie oral anticoagulation therapy) for patients with 1 or more non-sex CHA2DS2VASc stroke risk factors. For patients with a single non-sex CHA2DS2VASc stroke risk factor, we suggest oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel; and for those at high risk of stroke (eg, CHA2DS2VASc ≥2 in males or ≥3 in females), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we recommend or suggest in favor of oral anticoagulation, we suggest using a NOAC rather than adjusted-dose vitamin K antagonist therapy. With the latter, it is important to aim for good quality anticoagulation control with a TTR >70%. Attention to modifiable bleeding risk factors (eg. uncontrolled blood pressure, labile INRs, concomitant use of aspirin or NSAIDs in an anticoagulated patient, alcohol excess) should be made at each patient contact, and HAS-BLED score used to assess the risk of bleeding where high risk patients (≥3) should be reviewed and followed up more frequently. Conclusions Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non-gender CHA2DS2VASc stroke risk factor(s).

U2 - 10.1016/j.chest.2018.07.040

DO - 10.1016/j.chest.2018.07.040

M3 - Article

JO - Chest

JF - Chest

SN - 0012-3692

ER -